9.2650
06-5月-25 13:25:36
15 分の遅延
株式
-1.1550
-11.08%
本日の幅
9.2650 - 10.6300
ISIN
N/A
ソース
NASDAQ
Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights
31 3 2025 07:30:00 提供 Nasdaq GlobeNewswire
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease
07 2 2025 08:00:00 提供 Nasdaq GlobeNewswire